After Blood Plasma Emergency Use Authorization, Can Takeda Develop A More Potent Alternative?

Hyperimmune Globulin Could Prove Superior

After the FDA's emergency use authorization for convalescent plasma, pushed on by President Trump, an alliance of firms is working with the NIH to conduct a robust study of a potentially more potent alternative.

Covid19_Plasma
Hyperimmune-globulin (H-Ig) is a more advanced version of convalescent plasma, which the alliance hope to demonstrate the benefits of in an NIH-sponsored trial.

A group of companies calling itself the “CoVIg-19 Plasma Alliance”, led by Takeda Pharmaceutical Company Limited. and CSL Behring, is poised to start a randomized trial for hyperimmune globulin – a potentially more potent and convenient alternative to convalescent plasma therapy.

The move is significant as convalescent plasma has just been given an Emergency Use Authorization (EUA) by the US Food...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip